Varian LC/MS Application Note #16 Simultaneous Detection of CYP3A4, CYP2D6 and CYP2C9 Metabolites with a Single Sensitiv

About this manual

This document details an analytical method using Liquid Chromatography-Tandem Mass Spectrometry (LC-ESI-MS/MS) to characterize three specific drug metabolites: the hydroxylation of midazolam for CYP3A4, hydroxylation of tolbutamide for CYP2C9, and O-demethylation of dextromethorphan for CYP2D6. The method is designed for in vitro kinetic studies or detection in complex matrices like plasma or urine following solid-phase extraction (SPE).

The note specifies the required Varian instrumentation, including ProStar solvent delivery modules, a 1200L LC/MS system with an ESI source, and a ProStar 430 Autosampler. It provides detailed mass spectrometry conditions, such as ionization mode, collision gas pressure, and specific precursor/product ions for each analyte, along with the liquid chromatography gradient program.

What's inside

• Introduction
• Instrumentation
• Materials and Reagents
• Sample Preparation
• Mass Spectrometry Conditions
• LC Conditions
• MS/MS Scan Parameters
• Calibration Curves
• Discussion
• Conclusion

Specifications

Frequently asked questions

Which metabolites are detected in this method?

The method detects the hydroxylation of midazolam (CYP3A4), hydroxylation of tolbutamide (CYP2C9), and O-demethylation of dextromethorphan (CYP2D6).

What is the limit of quantitation for each metabolite?

The limits of quantitation are 1.0 pg for 4-hydroxytolbutamide, and 0.5 pg for both -hydroxymidazolam and dextrorphan.